TO EVALUATE THE MAGNITUDE OF DEPRESSION IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL

Authors

  • VIJAY KUMAR SINGH Department of Pharmacology, Rani Durgavati Medical College, Banda, Uttar Pradesh, India. https://orcid.org/0000-0001-7452-5545
  • VIRENDRA KUSHWAHA Department of Pharmacology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.
  • POOJA AGRAWAL Department of Pharmacology, Rani Durgavati Medical College, Banda, Uttar Pradesh, India.
  • VEERENDRA SINGH YADAV Department of Pharmacology, Rani Durgavati Medical College, Banda, Uttar Pradesh, India. https://orcid.org/0000-0002-8373-5242
  • DHANANJAY CHAUDHARY Department of Psychiatry, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i3.46742

Keywords:

Tuberculosis, Multi drug resistant tuberculosis, Depression, Hamilton depression rating scale, Psychiatric disorder

Abstract

Objective: The objective of the study was to evaluate the magnitude of depression in multidrug-resistant tuberculosis patients in a tertiary care teaching hospital.

Methods: An observational study was carried out in department of Psychiatry and department of Tuberculosis and Respiratory disease G.S.V.M. Medical College, Kanpur for a period of 9 months. The diagnosed multidrug-resistance tuberculosis (MDR-TB) patients coming to in-patient and out-patient department of tuberculosis and respiratory disease taking RNTCP regimen (Category IV) for MDR-TB will be screened for depression applying Hamilton Depression Rating Scale (HDRs) score and those patients who showed depression in screening will further send to psychiatry department for the final diagnosis of depression. We also categorized the patients into mild, moderate, and severe depression according to HDRs score. Data were tabulated in Microsoft Excel sheet. All categorical variables were analyzed using percentage.

Results: We screened 148 MDR TB patients who were taking drug for MDRTB. The average duration of treatment were 5.19 Month. Out of 148 patients, 56 (37.84%) patients were found to be suffering from depression. Out of 56 Depressed MDR TB Patients, 35 (62.5%) were male and 21 (37.5%) were female patients and 26 (46.43%) were mild (HDRS Score-8–13), 28 (50%) were moderate (HDRS Score-14–18) and 2 (3.57%) were severely depressed (HDRS Score-19–20).

Conclusion: The magnitude of depression in MDR TB Patients taking RNTCP regimen (Category IV) for MDR TB was 37.84% and out of these patients, 46.43% were mild, 50% were moderate, and 3.57% were severely depressed.

Downloads

Download data is not yet available.

Author Biographies

VIRENDRA KUSHWAHA, Department of Pharmacology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.

PROFESSOR, DEPARTMENT OF PHARMACOLOGY

POOJA AGRAWAL, Department of Pharmacology, Rani Durgavati Medical College, Banda, Uttar Pradesh, India.

Department of Pharmacology

Pofessor & Head

VEERENDRA SINGH YADAV, Department of Pharmacology, Rani Durgavati Medical College, Banda, Uttar Pradesh, India.

DEPARTMENT  OF PHARMACOLOGY

ASSISTANT PROFESSOR 

DHANANJAY CHAUDHARY, Department of Psychiatry, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India.

DEPARTMENT OF PSYCHIATRY

PROFESSOR & HEAD

References

Singh H, Kaur K, Girish P. Multidrug Resistant tuberculosis: A pharmacological view based on revised national tuberculosis control programme dots-plus guidelines. IOSR J Pharm 2012;2:62-8.

India TB; 2017. p. 9. Available from: https://www.tbcindia.gov.in/writereaddata/tb%20india%202017.pdf [Last accessed on 2017 Mar 24].

Islam AT, Hoque A, Tarannum R. Pattern of psychiatric illness among tuberculosis patients an analysis in a tertiary care hospital of Bangladesh. Int J Appl Res 2015;1:763-6.

Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Fawzi MC, et al. Psychiatric issues in the management of patients with multidrug resistant tuberculosis. Int J Tuberc Lung Dis 2004;8:749-59. PMID 15182146

Pachi A, Bratis D, Moussas G, Tselebis A. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberc Res Treat 2013;2013:489865. doi: 10.1155/2013/489865, PMID 23691305

World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis; 2014. p. 106. Available from: https://www.apps.who.int/ iris/handle/10665/130918 [Last accessed on 2017 Jul 27].

Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011;13:7-23. doi: 10.31887/DCNS.2011.13.1/wkaton, PMID 21485743

Basu G, Chatterjee C, Singh R, Biswas S. Prevalence of depression in tuberculosis patients: An experience from a DOTS clinic. IJRRMS 2012;2:14-7.

Lykouras E, Ioannidis H, Voulgaris D. Depression in general hospital patients: Preliminary results. Arch Hell Med 1987;4:287-9.

Tripathi KD. Essential of Medical Pharmacology.7th ed. India: The Health Sciences Publisher; 2013. p. 775, 776.

Dahiya S, Khichi SK, Goel PK, Singh A, Singh NK. Prevalence of depression among tuberculosis patients. Sch J App Med Sci 2017;5:2212-15.

Dawar U, Garg A, Oswal R, Patel KR. A study of prevalence of depression in patients with multi drug resistant tuberculosis. Eur Respir J 2016;48:2690. doi:10.1183/13993003.

Mehreen S, Khan MA, Basit A, Khan A, Ashiq N, Javaid A. Frequency of depression in multidrug-resistant tuberculosis patients: An experience from a tertiary care hospital. Pak J Chest Med 2015;21:149-4.

Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:648-55. PMID 11467371

Published

07-03-2023

How to Cite

SINGH, V. K., V. KUSHWAHA, P. AGRAWAL, V. S. YADAV, and D. CHAUDHARY. “TO EVALUATE THE MAGNITUDE OF DEPRESSION IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 3, Mar. 2023, pp. 102-4, doi:10.22159/ajpcr.2023.v16i3.46742.

Issue

Section

Original Article(s)